Polyamine transporter selective compounds as anti-cancer agents
US-9598351-B2 · Mar 21, 2017 · US
US9926260B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9926260-B2 |
| Application number | US-201615138531-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 26, 2016 |
| Priority date | Mar 28, 2012 |
| Publication date | Mar 27, 2018 |
| Grant date | Mar 27, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a compound according to Formula I: R′HN—(CH 2 ) x —NH—(CH 2 ) y —NH—CH 2 —R—CH 2 —NH—(CH 2 ) xx —NH—(CH 2 ) yy —NHR″ (I) wherein R is selected from the group consisting of anthracene, naphthalene, and benzene; wherein R′ and R″ are each independently an alkyl group; wherein x, xx, y, and yy are independently selected from the group consisting of 3 and 4; or a pharmaceutically acceptable salt thereof; and difluoromethylomithine (DFMO), at least one chemotherapeutic agent, or both. 2. The composition of claim 1 , wherein R′ and R″ are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, and butyl. 3. The composition of claim 2 , wherein R′ and R″ are each methyl. 4. The composition of claim 1 , wherein x, xx, y, and yy are each 4. 5. The composition of claim 1 , wherein x, xx, y, and yy are each 3. 6. The composition of claim 1 , wherein R′ and R″=methyl, wherein x, xx, y, and yy are each 4, and wherein R=anthracene. 7. The composition of claim 1 , wherein R′ and R″=methyl, wherein x, xx, y, and yy are each 4, and wherein R=naphthalene. 8. The composition of claim 1 , wherein R′ and R″=methyl, wherein x, xx, y, and yy are each 4, and wherein R=benzene. 9. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier. 10. A method for inhibiting polyamine transport in cells of a subject having an active polyamine transport system, the method comprising administering to the subject a composition of claim 1 in an amount effective to reduce polyamine transport in the cells. 11. The method of claim 10 , wherein the composition further comprises a pharmaceutically acceptable carrier. 12. The method of claim 10 , wherein R′ and R of Formula III are methyl and anthracene, respectively. 13. The method of claim 10 , wherein R′ and R of Formula III are methyl and naphthalene, respectively. 14. The method of claim 10 , wherein R′ and R of Formula III are methyl and benzene, respectively. 15. A method of inhibiting the growth of a cell, the method comprising contacting the cell with an effective amount of a composition of claim 1 such that the cell is targeted via its active polyamine transport system and its growth is inhibited. 16. A method for inhibiting polyamine transport in cells of a subject having an active polyamine transport system, the method comprising administering to the subject a composition in an amount effective to reduce polyamine transport in the cells, wherein the composition comprises a compound of the following formula: wherein R is selected from the group consisting of anthracene, naphthalene, and benzene; and wherein each R′ is independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, and butyl; or a pharmaceutically acceptable salt of said compound; and difluoromethylornithine (DFMO), at least one chemotherapeutic agent, or both.
Antineoplastic agents · CPC title
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
the six-membered aromatic ring being part of a condensed ring system formed by at least three rings · CPC title
Polyalkylene(poly)amines · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.